Skip to main navigation

Menu

Skip to content

Investors

Alnylam

E-mail Alerts

Download Center

Print

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter

Financial Information

FinancialMenu

Fundamentals
Financial Information
Quarterly Results
Key Ratios
Annual Reports

Here you will find a summary of Alnylam Pharmaceuticals, Inc.'s latest financial information.

Show all

Latest Earnings Release and 10-Q

Fourth Quarter Financial Results
Form 10-Q

Show all

Latest Annual Report and 10-K

2016 Annual Report
Form 10-K

Show all

Latest Proxy Statement

Latest Proxy Statement

Share Related Items

Market Capitalization (Mil)	$9,786.75
Shares Outstanding (Mil)	$100.17
Shares Outstanding, Average (FY) (Mil)	$90.55
Float (Mil)	$88.72

Copyright Thomson Reuters Corporation

FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.

Search

Recent Press Releases

View all releases

Apr 14,2018

Summary Toggle Alnylam Presents New Positive Clinical Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Mar 28,2018

Summary Toggle Alnylam and Collaborators to Present Clinical Study Results in Acute Hepatic Porphyrias (AHPs) at The 53rd International Liver Congress™ of the European Association for the Study of the Liver (EASL)
Mar 28,2018

Summary Toggle Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis

View all releases

: (Common):

Price:
Change (%):
Volume:
Data as of Copyright NASDAQ. Minimum 15 minutes delay

twitter
linkedin
youtube
rss

Copyright © 2018 Alnylam Pharmaceuticals, Inc. --- All Rights Reserved --- Glossary | Media Kit | Legal | Privacy Policy | Site Map